International Journal of Drug Policy
Volume 22, Issue 1 , Pages 16-25 , January 2011

Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes

  • Montserrat Neira-León

      Affiliations

    • Secretaría Plan Nacional sobre el Sida, Spain
    • ,
  • Gregorio Barrio

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Escuela Nacional de Sanidad. Instituto de Salud Carlos III, Madrid, Spain
    • ,
  • María J. Bravo

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Madrid, Spain
    • ,
  • M. Teresa Brugal

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Agència de Salut Pública de Barcelona, Spain
    • ,
  • Luis de la Fuente

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Madrid, Spain
    • ,
  • Antonia Domingo-Salvany

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Drug Abuse Epidemiology Research Group, IMIM-Hospital del Mar, Barcelona, Spain
    • ,
  • José Pulido

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Madrid, Spain
    • Corresponding Author InformationCorresponding author at: Centro Nacional de Epidemiología, Instituto de Salud Carlos III, C/Monforte de Lemos, 5, 28029 Madrid, Spain. Tel.: +34 918222675; fax: +34 913877815.
    • ,
  • Sara Santos

      Affiliations

    • CIBER Epidemiología y Salud Pública (CIBERESP), Spain
    • Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Madrid, Spain
    • ,
  • Project Itinere Group

      Affiliations

    • The Itínere Project Group consists of the previously cited authors as well as: Albert Espelt, Yolanda Castellano, Fermín Fernández, Francisco González, Teresa C Silva, Daniel Lacasa, Noelia LLorens, Eusebio Mejías, Gemma Molist, Luis Sordo and Fernando Vallejo.

Received 22 December 2009 ,Revised 18 June 2010 ,Accepted 28 June 2010.

References 

  1. Agencia Antidroga de la Comunidad de Madrid . Memoria 2001 [Annual Report 2001]. Madrid: Agencia Antidroga de la Comunidad de Madrid (AACM); 2002;
  2. Agencia Antidroga de la Comunidad de Madrid . Memoria 2002 [Annual Report 2002]. Madrid: Agencia Antidroga de la Comunidad de Madrid (AACM); 2003;
  3. Agencia Antidroga de la Comunidad de Madrid . Memoria 2003 [Annual Report 2003]. Madrid: Agencia Antidroga de la Comunidad de Madrid (AACM); 2004;
  4. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005;100:1823–1831
  5. Bravo MJ, Barrio G, de la Fuente L, Royuela L, Domingo L, Silva T. Reasons for selecting an initial route of heroin administration and for subsequent transitions during a severe HIV epidemic. Addiction. 2003;98:749–760
  6. Bravo MJ, Royuela L, Barrio G, de la Fuente L, Suarez M, Brugal MT. More free syringes, fewer drug injectors in the case of Spain. Social Science & Medicine. 2007;65:1773–1778
  7. Bravo MJ, Royuela L, de la Fuente L, Brugal MT, Barrio G, Domingo-Salvany A, et al. Use of supervised injection facilities and injection risk behaviors among young drug injectors. Addiction. 2009;104:614–619
  8. Brugal MT, Barrio G, de la Fuente L, Regidor E, Royuela L, Suelves JM. Factors associated with non-fatal heroin overdose: Assessing the effect of frequency and route of heroin administration. Addiction. 2002;97:319–327
  9. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100:981–989
  10. Darke S, Hall W. Heroin overdose: Research and evidence-based intervention. Journal of Urban Health. 2003;80:189–200
  11. Darke S, Zador D. Fatal heroin ‘overdose’: A review. Addiction. 1996;91:1765–1772
  12. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction. 1996;91:405–411
  13. Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson M. Patterns of nonfatal heroin overdose over a 3-year period: Findings from the Australian treatment outcome study. Journal of Urban Health. 2007;84:283–291
  14. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, et al. Risk of fatal overdose during and after specialist drug treatment: The VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102:1954–1959
  15. de la Fuente L, Bravo MJ, Lew C, Barrio G, Soriano V, Royuela L. Prevalencia de infección por el virus de la inmunodeficiencia humana y de conductas de riesgo entre los consumidores de heroína de Barcelona, Madrid y Sevilla: un ejemplo de las ventajas de centrar los estudios en los consumidores y no sólo en los usuarios por vía intravenosa [The prevalence of human immunodeficiency virus infection and the risk behaviors in the heroin addicts of Barcelona Madrid and Seville: An example of the advantages of centering studies on addicts and not just on intravenous users]. Medicina Clinica. 1999;113:646–651
  16. de la Fuente L, Brugal MT, Ballesta R, Bravo MJ, Barrio G, Domingo-Salvany A, et al. Metodología del estudio de cohortes del Proyecto Itinere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes [Cohort study methodology of the Itinere Project on heroin users in three Spanish cities and main characteristics of the participants]. Revista Española de Salud Pública. 2005;79:475–491
  17. de la Fuente L, Bravo MJ, Toro C, Brugal MT, Barrio G, Soriano V, et al. Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. Journal of Epidemiology and Community Health. 2006;60:537–542
  18. de la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-León M, Barrio G. Más de treinta años de drogas ilegales en España: una amarga historia con algunos consejos para el futuro. Revista Española de Salud Pública. 2006;80:505–520
  19. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, Gribble J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. The Lancet. 1999;353:1657–1661
  20. Delegación del Gobierno para el Plan Nacional sobre Drogas . Estrategia Nacional sobre Drogas. Plan de Acción 2005–2008 [National strategy on drugs. Action plan 2005–2008]. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministrerio de Sanidad y Consumo; 2005;
  21. Delegación del Gobierno para el Plan Nacional sobre Drogas . Memoria 2004 [Annual Report 2004]. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministerio de Sanidad y Consumo; 2006;
  22. Delegación del Gobierno para el Plan Nacional sobre Drogas . Observatorio Español sobre Drogas (OED). Informe 2005–2006. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD). Ministerio de Sanidad y Consumo; 2008;
  23. Dietze P, Jolley D, Fry CL, Bammer G, Moore D. When is a little knowledge dangerous? Circumstances of recent heroin overdose and links to knowledge of overdose risk factors. Drug and Alcohol Dependence. 2006;84:223–230
  24. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health. 2009;99:788–791
  25. European Monitoring Center for Drugs and Drug Addiction . The state of the drugs problem in Europe. Annual Report 2008. Luxembourg: European Monitoring Center for Drugs and Drug Addiction (EMCDDA); 2008;
  26. European Monitoring Center for Drugs and Drug Addiction . The state of the drugs problem in Europe. Annual Report 2009. Luxembourg: European Monitoring Center for Drugs and Drug Addiction (EMCDDA); 2009;
  27. Espelt A, Queralt A, Graugés D, García V, Vecino C, Brugal MT. Actualització dels Indicadors de Drogues. 4 Trimestre 2008 [Update of Drug Indicators. 4th Quarter 2008]. Barcelona: Agència de Salud Pública; 2009;
  28. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in Sexual and Injection Risk Behavior Among Active Young Injection Drug Users in San Francisco (the UFO study). Journal of Urban Health. 2003;80:137–146
  29. Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103:251–255
  30. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City. Addictive Behaviors. 2005;31:907–912
  31. Gonzalez-Saiz F, Lozano OM, Ballesta R, Silva T, Brugal MT, Bilbao I, et al. Validity of the Severity of Dependence Scale (SDS) construct applying the item response theory to a non-clinical sample of heroin users. Substance Use & Misuse. 2008;43:919–935
  32. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The severity of dependence scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–614
  33. Gossop M, Griffiths P, Powis B, Williamson S, Strang J. Frequency of non-fatal heroin overdose: Survey of heroin users recruited in non-clinical settings. British Medical Journal. 1996;313:402
  34. Green TC, Grau LE, Blinnikova KN, Torban M, Krupitsky E, Ilyuk R, et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. International Journal of Drug Policy. 2009;20:270–276
  35. Heckathorn DD. Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems. 1997;44:174–179
  36. Hedrich D. European report on drug consumption rooms. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004;
  37. Ilundain E. Drogas, enfermedad y exclusión ¿Can Tunis (Barcelona) como paradigma? [Drugs, illness and exclusion ¿Can Tunis (Barcelona) as paradigm?]. Barcelona: Fundación Medicina y Humanidades Médicas; 2009;
  38. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health. 2001;91:774–780
  39. McGregor C, Darke S, Ali R, Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: Circumstances and risk perceptions. Addiction. 1998;93:701–711
  40. Ministerial Council on Drug Strategy . National heroin overdose strategy. Camberra: Commonwealth of Australia; 2001;
  41. Moore D. Governing street-based injecting drug users: A critique of heroin overdose prevention in Australia. Social Science & Medicine. 2004;59:1547–1557
  42. Morgan O, Vicente J, Griffiths P, Hickman M. Trends in overdose deaths from drug misuse in Europe: What do the data tell us?. Addiction. 2008;103:699–700
  43. MSIC Evaluation Committee . Final report on the evaluation of the Sydney medically supervised injecting centre. Sydney: Authors; 2003;
  44. Neira-León M, Barrio G, Brugal MT, de la Fuente L, Ballesta R, Bravo MJ, et al. Do young heroin users in Madrid, Barcelona and Seville have sufficient knowledge of the risk factors for unintentional opioid overdose?. Journal of Urban Health. 2006;83:477–496
  45. Newman JC, Des Jarlais DC, Turner CF, Gribble J, Cooley P, Paone D. The differential effects of face-to-face and computer interview modes. American Journal of Public Health. 2002;92:294–297
  46. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, et al. Evaluation of a naloxone distribution and administration program in New York City. Substance Use & Misuse. 2008;43:858–870
  47. Powis B, Strang J, Griffiths P, Taylor C, Williamson S, Fountain J, et al. Self-reported overdose among injecting drug users in London: Extent and nature of the problem. Addiction. 1999;94:471–478
  48. Rhodes T. Risk environments and drug harms: A social science for harm reduction approach. International Journal of Drug Policy. 2009;20:193–201
  49. Ruttenber AJ, Kalter HD, Santinga P. The role of ethanol abuse in the etiology of heroin-related death. Journal of Forensic Sciences. 1990;35:891–900
  50. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: A pilot intervention study. Journal of Urban Health. 2005;82:303–311
  51. Secretaria del Plan Nacional sobre Sida . ICAP Informe del cuestionario de actividades de prevención del VIH en las Comunidades Autónomas [ICAP. Report from the HIV prevention activities questionnaire in the Authonomous Communities]. 2009;Retrieved 3 October 2009 from http://www.msc.es/gl/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/ICAP2007/ICAP2007.pdf
  52. Sporer KA. Acute heroin overdose. Annals of Internal Medicine. 1999;130:584–590
  53. Sporer KA. Strategies for preventing heroin overdose. British Medical Journal. 2003;326:442–444
  54. Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: An examination of individual, social and setting correlates. Addiction. 2005;100:397–404
  55. Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. Evaluation of the Staying Alive programme: Training injection drug users to properly administer naloxone and save lives. International Journal of Drug Policy. 2009;20:131–136
  56. Trujols J. Take home naloxone: Life-saving intervention, medico-legal concern and heroin users’ competence. British Medical Journal. 2001;322:895–896
  57. Vallejo F, Toro C, de la Fuente L, Brugal MT, Barrio G, Soriano V, et al. Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. Journal of Substance Abuse Treatment. 2007;34:398–406
  58. van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addictive Behaviors. 1999;24:559–563
  59. Vicente J, Giraudon I, Matías J, Hedrich D, Wiessing L. Rebound of overdose mortality in the European Union 2003–2005: Findings from the 2008 EMCDDA Annual Report. Eurosurveillance. 2009;14:

PII: S0955-3959(10)00098-8

doi: 10.1016/j.drugpo.2010.06.003

International Journal of Drug Policy
Volume 22, Issue 1 , Pages 16-25 , January 2011

Article Tools